This is the first position review I have written about. However, I want to start providing updates on positions and clinical trial...

A follow-up on UroGen's upcoming PDUFA

This post details the upcoming UroGen PDUFA on June 13th.

This article details why XPro and Inmune Bio will fail their Alzheimer's Phase 3 results.

Executive Summary - Praxis is a short going into interim results. Praxis Precision Medicines is developing Ulixacaltamide, a small...